AIM-listed animal feed additive firm Anpario (ANP) has lifted its full-year revenue and earnings guidance. The company cited stronger than expected year-end demand, helped by its Bio-Vet product range.
| Share price: 500p (+4.2%) | PE: 16.8x |
| Market cap: £103m | Yield: 2.4% |
OPERATIONAL GEARING
Anpario enjoyed stronger than anticipated H2 demand, meaning full year revenue will be around £47.1 million. That’s up 23% on 2024 and compares with the consensus forecast of £45.5 million ahead of today’s announcement.
Thanks to the group’s strong operational gearing, operating profit rises faster the more revenue it generates. As a result, EBITDA is seen up 34% at not less than £9.4 million against a consensus of £8.2 million.
The group delivered broad-based growth with Asia, Europe and the Americas all ahead of 2024. While sales in India also grew, Middle East and Africa revenue declined due to tough comparatives.
The results include a full-year contribution from Bio-Vet, which was acquired in September 2024. Bio-Vet saw one of its highest ever six-month sales periods in the second half of 2025.
This is a stand-out performance by Anpario and analysts will have to go back to their calculators. The firm is seeing strong growth across the board, and the Bio-Vet acquisition has played out well.
The firm has a strong balance sheet, which means it continue to invest in value-added product solutions. It also has the option to look for more earnings-enhancing acquisitions to supplement underlying growth.
We note the success of animal vaccine maker Genus (GNS), which recently raised its earnings guidance for a second time. The animal health market seems to be growing faster than analysts think, so both stocks are on our watch list.
Read the press release here: https://www.anpario.com/investor/
For news on Genus, see here: https://sharesify.com/genus-earnings-to-beat-expectations/
Disclaimer: This content is for information only and is not investment advice. Always do your own research before investing. Click here to see full disclaimer.
